Danhong injection for the treatment of early diabetic nephropathy

Abstract

Background: Diabetic nephropathy (DN) is the one that of the most common complications of diabetes mellitus (DM). Diabetic patients will experience a high mortality rate when DN progress to end-stage. So, it is extremely important to early treat DN. Although several interventions have been used to treat DN, a conclusive finding has not already been achieved. As one of the most common Chinese medicines, danhong injection (DHI) which has been shown to have various functions has also been prescribed to be as the alternative treatment option. However, no systematic review and meta-analysis has been conducted to objectively and comprehensively investigate its effectiveness and safety. Thus, we designed the current systematic review and meta-analysis to answer whether DHI can be preferably used to timely treat DN. Methods: We will perform a systematic search to capture any potentially eligible studies in several electronic databases including PubMed, Cochrane library, Embase, China National Knowledgement Infrastructure (CNKI), Wanfang database, and Chinese sci-tech periodical full-text database (VIP) from their inception to August 31, 2020. We will assign 2 independent reviewers to select eligible studies, and assess the quality of included studies with Cochrane risk of bias assessment tool. We will perform all statistical analyses using RevMan 5.3 software. Ethics and dissemination: We will submit our findings to be taken into consideration for publication in a peer-reviewed academic journal. Meanwhile, we will also communicate our findings in important conferences. Protocol registry: The protocol of this systematic review and meta-analysis has been registered at the International Plateform of Registered Systematic Review and Meta-Analysis Protocols (INPLASY) platform ( https://inplasy.com/inplasy-2020-9-0005/ , registry number: INPLASY202090005) and this protocol was funded through a protocol registry.

Buckwheat and Cardiometabolic Health: A Systematic Review and Meta-Analysis

“…Additionally, such effects are hypothetically attributed to resistant starch, protein, and phenolic substances in the grain, and to the interactions among these constituents, without any methodological high-quality study design in humans supporting these claims. Of note, in the systematic review part of our report, several studies used Tatary BW as intervention [21][22][23][25][26][27].…”

“…The included studies involved eight-hundred and thirty-one participants and among them, only eight could be included in meta-analyses (n = 464 participants) (Figure 1). Six studies were conducted in Europe [17][18][19][20][21], eight in Asia-Pacific [22][23][24][25][26][27][28][29], one in Africa (Egypt) [30] and one in North America (Canada) [31]. Summarized results for the meta-analyses are provided in supplementary Table S3.…”

“…Concerning glucose homeostasis, two studies found statistically significant reductions in glycated hemoglobin (HbA1c) after using non-grain components for the BW intervention [20,26]. Two other studies using grain components of Tatary BW did not find any effect on HbA1c [23,27].…”

“…It is uncertain how BW can influence HbA1c, as some of these studies lacked a control group and others had similar changes in HbA1c in the control group. In one the studies, BW intervention was not clearly described and was compared head-to-head with a drug among T2D patients [26].…”

Ethnobotany, phytochemistry and pharmacological properties of Fagopyri Dibotryis Rhizoma: A review

“…FDR leaf tea reduced blood glucose, blood lipids and MDA activity, increased SOD activity and improved pancreatic and liver lesions in mice with T2DM ( Huang X et al, 2014 ). The FDR mixture significantly improved the clinical symptoms of diabetic nephropathy and significantly reduced the patient’s blood glucose, glycosylated hemoglobin and blood lipids ( Huang et al, 2009 ).…”